Crit Care Med:性别对心肺复苏结果的影响:一项随机前瞻性模拟研究

2017-06-21 MedSci MedSci原创

实施者的性别对心肺复苏结果的影响一直都没有研究过,但是这可能将来会对教学方向产生重大的影响。本研究的目的旨在对比女性和男性医师在心肺复苏能力及领导水平。此研究为一项前瞻性、随机性模拟研究。研究对象为瑞士的两所大学216名医学生志愿者(108名女性和108名男性),他们将被分为3人为一个小组。患者为瑞士巴塞尔大学附属医院医学ICU模拟中心的病人。 我们分别针对小组和个人的数据都进行了分析。对小

实施者的性别对心肺复苏结果的影响一直都没有研究过,但是这可能将来会对教学方向产生重大的影响。本研究的目的旨在对比女性和男性医师在心肺复苏能力及领导水平。此研究为一项前瞻性、随机性模拟研究。研究对象为瑞士的两所大学216名医学生志愿者(108名女性和108名男性),他们将被分为3人为一个小组。患者为瑞士巴塞尔大学附属医院医学ICU模拟中心的病人。

我们分别针对小组和个人的数据都进行了分析。对小组的分析主要结果采取心脏骤停后前180s的实际复苏时间。与男子组相比,女子组实际复苏的时间较短(mean±SD)(87+41 vs 109±33s;p=0.037)、胸外按压前耽误时间较长(109±77 vs 70±56s;p=0.038)。另外,与男子组相比,女子组在不同的专业领域中都表现出的领导水平较男子组低,而且主动提供心肺复苏的较少。对个人的分析仅做了混合小组的分析,实验说明女性更加缺乏抢救中的领导能力(3±2 vs 5±3;p=0.027)。使用回归分析对小组的组成进行分析。

综上所述,我们发现性别对心肺复苏有极大的影响,女性施救者在心肺复苏过程中表现较为逊色,主要表现在提供心肺复苏的主动性以及领导能力上。所以将来心肺复苏教学上应该将医学生的性别纳入考虑因素。

原始出处:

Amacher SA1, Schumacher C, Legeret C,et al. Influence of Gender on the Performance of Cardiopulmonary Rescue Teams: A Randomized,Prospective Simulator Study. Crit Care Med. 2017 Jul;45(7);1184-1191. doi: 10.1097/CCM.0000000000002375.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2006381, encodeId=52dd200638145, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Sep 17 23:41:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684450, encodeId=39eb16844508a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Feb 15 11:41:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216113, encodeId=d05f216113e3, content=真是什么样的idea 都有, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Tue Jun 27 23:55:02 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305404, encodeId=9c7f130540428, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607689, encodeId=10db160e689c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2006381, encodeId=52dd200638145, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Sep 17 23:41:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684450, encodeId=39eb16844508a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Feb 15 11:41:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216113, encodeId=d05f216113e3, content=真是什么样的idea 都有, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Tue Jun 27 23:55:02 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305404, encodeId=9c7f130540428, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607689, encodeId=10db160e689c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2018-02-15 aids222
  3. [GetPortalCommentsPageByObjectIdResponse(id=2006381, encodeId=52dd200638145, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Sep 17 23:41:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684450, encodeId=39eb16844508a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Feb 15 11:41:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216113, encodeId=d05f216113e3, content=真是什么样的idea 都有, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Tue Jun 27 23:55:02 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305404, encodeId=9c7f130540428, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607689, encodeId=10db160e689c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-27 若轩

    真是什么样的idea 都有

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2006381, encodeId=52dd200638145, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Sep 17 23:41:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684450, encodeId=39eb16844508a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Feb 15 11:41:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216113, encodeId=d05f216113e3, content=真是什么样的idea 都有, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Tue Jun 27 23:55:02 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305404, encodeId=9c7f130540428, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607689, encodeId=10db160e689c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]
    2017-06-23 lizhou0204
  5. [GetPortalCommentsPageByObjectIdResponse(id=2006381, encodeId=52dd200638145, content=<a href='/topic/show?id=924a3264381' target=_blank style='color:#2F92EE;'>#前瞻性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32643, encryptionId=924a3264381, topicName=前瞻性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5cb32500112, createdName=1508842480_96220437, createdTime=Sun Sep 17 23:41:00 CST 2017, time=2017-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1684450, encodeId=39eb16844508a, content=<a href='/topic/show?id=dfae5133e1d' target=_blank style='color:#2F92EE;'>#心肺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51337, encryptionId=dfae5133e1d, topicName=心肺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8e128082444, createdName=aids222, createdTime=Thu Feb 15 11:41:00 CST 2018, time=2018-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=216113, encodeId=d05f216113e3, content=真是什么样的idea 都有, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLS3nbTc0lzBwDxSVnm5KA9vNmsZrjTSvKlld6teMf4RG4ZmZWRvC80GB7zl4TSib3BAoZgcCYpzxQ/132, createdBy=02681961038, createdName=若轩, createdTime=Tue Jun 27 23:55:02 CST 2017, time=2017-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305404, encodeId=9c7f130540428, content=<a href='/topic/show?id=270342e249d' target=_blank style='color:#2F92EE;'>#复苏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42724, encryptionId=270342e249d, topicName=复苏)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1d01326, createdName=lizhou0204, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607689, encodeId=10db160e689c8, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jun 23 00:41:00 CST 2017, time=2017-06-23, status=1, ipAttribution=)]

相关资讯

AM J CARDIOL:压力是冠心病的危险因素,与性别无关

压力,尤其是女性的压力,正越来越多地被认为是冠心病的主要危险因素,冠心病是由于炎症、栓塞等导致冠状动脉血管管腔狭窄或闭塞引起的心脏病。在一项新的研究中,加州大学洛杉矶分校的研究人员推测,简单的生物标志物--尿液中的应激激素多巴胺、肾上腺素、去甲肾上腺素和肾上腺皮质激素--与冠状动脉中的钙离子浓度有关,这些生物标志物提示冠心病的存在,且这种作用在女性中的表现强于男性。然而,研究人员发现,实际上这种关

Plos One:身体形态指数(ABSI)与死亡率有关!

虽然身体质量指数(BMI)是目前使用最广泛的人体测量方法,但其与全因死亡率的关联通常为J形或U形。身体形态指数(ABSI)是最近制定的人体测量方法,其显示出与全因死亡率的线性关系,特别是在白种人队列中。近期,一项发表在杂志Plos One上的研究旨在评估亚洲人的ABSI和全因死亡率之间的关系,并评估性别差异和慢性肾脏疾病(CKD)对这种关系的影响。此项研究是一项纵向队列研究,评估日本全国特定健康检

Int J Cardiol:年龄和性别对先天性心脏病成人存活率和死亡原因的影响!

由此可见,女性CHD患者的死亡率比男性要高。随着年龄的增长,CV死亡有所降低,但CV死亡的原因发生了重大的暂时性变化。在40以上的患者中,心脏衰竭超过猝死是幸存者的主要死亡原因。

当护士,性别真的很重要吗?

男生相对于女生来说在很多方面都有独特的优势,尤其是在一些大学专业中更是有很多限制为男生报考,但对于一些偏女性化的大学专业,很多也是适合男生的,而且在就业及后期的发展中,男生更加有优势。例如在护理界中,男护士的作用愈加明显。医院有男医生和女医生,大家各司其职;可是医院里的男护士却少得可怜,很多医院甚至是一名男护士也没有,这些年来,护士妹妹一直被当做男生使,呼吁男护士的加入,成了护士姐妹们的心声。

JASN:性别与肾移植失败的风险之间的相关性受年龄影响吗?

这些观察结果可能由几个因素的综合影响来解释,包括性别确定的轻微组织相容性抗原的识别、性激素对免疫激活的影响、药物依从性的性别和年龄相关的差异以及身体大小的性别相关差异。此外,进一步的研究应该确定对肾移植接受者是否有必要进行性别和年龄特异性的免疫抑制策略。

PLos One:他汀类药物与男性的运动能力受损有关!

运动和他汀类药物均可以减少心血管疾病(CVD)的发生。运动能力可以通过心肺运动测试(CPET)进行评估。但是,目前尚不清楚他汀类药物是否与CPET的参数相关联。近期,一项发表在杂志PLos One上的研究调查评估了在普通人群中,他汀类药物与CPET的运动能力是否有关。此项研究将波美拉尼亚卫生研究(SHIP)的两个独立队列的横断面数据进行了合并(n = 3,500; 50%的男性)。在症状限制性CP